GSK (LON:GSK) Insider Jonathan Symonds Acquires 2,500 Shares

GSK plc (LON:GSK) insider Jonathan Symonds acquired 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The stock was acquired at an average price of GBX 2,114 per share, with a total value of £52,850.

Jonathan Symonds also recently made the following trade(s):

• On Monday, December 22nd, Jonathan Symonds bought 1,650 shares of GSK stock. The shares were bought at an average price of GBX 1,810 per share, for a total transaction of £29,865.

GSK Stock Performance

Shares of GSK opened at GBX 2,180 on Friday. The firm has a market cap of £87.96 billion, a P/E ratio of 16.39, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,066. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The firm’s 50 day moving average price is GBX 1,846.14 and its two-hundred day moving average price is GBX 1,666.64.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Shore Capital Group restated a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a research note on Wednesday. Citigroup reaffirmed a “buy” rating and set a GBX 1,900 price target on shares of GSK in a research note on Tuesday, January 27th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Finally, UBS Group restated a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a report on Friday, January 23rd. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of GBX 1,867.86.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK Chair Sir Jonathan Symonds purchased 2,500 shares at GBX 2,114 (≈£52,850), signaling insider confidence. GSK Chair Sir Jonathan Symonds Buys Additional Shares in the Company
• Positive Sentiment: EU approved GSK’s Nucala for use in uncontrolled COPD — expands label and addressable market for an existing respiratory franchise. EU gives GSK’s Nucala green light for use in uncontrolled COPD
• Positive Sentiment: EU granted adult approval for GSK’s RSV vaccine — a major commercial milestone that supports revenue growth expectations for respiratory vaccines. GSK RSV Vaccine Wins EU Adult Approval As Shares Trade Above Targets
• Positive Sentiment: Brokerage action: Shore Capital reaffirmed a “buy” rating and GBX 2,300 target — provides independent support for upside vs. current levels. Broker Ratings
• Positive Sentiment: Q4 results beat: GSK reported stronger-than-expected Q4 profit and highlighted strategic execution — this underpins near-term earnings momentum. GSK PLC Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Market commentary/valuation pieces note a ~47% one-year share gain and debate whether the stock remains attractively valued — useful context for investors weighing further upside vs. valuation risk. Is GSK Still Attractive After A 47% One-Year Share Price Gain
• Negative Sentiment: Guidance caution: Management flagged a likely slowdown in sales growth for 2026 under the new CEO — raises near-term growth concerns and tempers the upbeat reaction to approvals and the quarter. GSK sees slower sales growth in 2026

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.